Angela Q. Maldonado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Angela Q. Maldonado has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Matthew J. Everly
Terasaki Research Institute, Los Angeles, California
6 shared publications C. Haisch
East Carolina University, Greenville, NC
5 shared publications- Charlie Morgan
East Carolina University, Greenville, NC
5 shared publications G. Dieplinger
Terasaki Foundation, Los Angeles
5 shared publicationsK. Briley
East Carolina University, Greenville, NC
5 shared publications- Lorita M. Rebellato
East Carolina University, Greenville, NC
5 shared publications
Latest Publications
- Open Access
- 4 December 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (4) , 878-880
Long-term outcomes at 5 years posttransplant in imlifidase-desensitized kidney transplant patients
- 4 December 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (4) , 878-880
Open AccessLong-term outcomes at 5 years posttransplant in imlifidase-desensitized kidney transplant patients
- Open Access
- 18 July 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (7) , e15383
A Randomized Trial Comparing Imlifidase to Plasmapheresis in Kidney Transplant Recipients With Antibody‐Mediated Rejection
Background: Antibody‐mediated rejection (ABMR) poses a barrier to long‐term graft survival and is one of the most challenging events after kidney transplantation. Removing donor specific antibodies (DSA) through therapeutic plasma exchange (PLEX) is a cornerstone of antibody depletion but has inconsistent effects. Imlifidase is a treatment currently utilized for desensitization with near‐complete inactivation of DSA both in the intra‐ and extravascular space.Methods: This was a 6‐month, randomized, open‐label, multicenter, multinational trial conducted at 14 transplant centers. Thirty patients were randomized to either imlifidase or PLEX treatment. The primary endpoint was reduction in DSA level during the 5 days following the start of treatment.Results: Despite considerable heterogeneity in the trial population, DSA reduction as defined by the primary endpoint was 97% for imlifidase compared to 42% for PLEX. Additionally, imlifidase reduced DSA to noncomplement fixing levels, whereas PLEX failed to do so. After antibody rebound in the imlifidase arm (circa days 6–12), both arms had similar reductions in DSA. Five allograft losses occurred during the 6 months following the start of ABMR treatment—four within the imlifidase arm (18 patients treated) and one in the PLEX arm (10 patients treated). In terms of clinical efficacy, the Kaplan–Meier estimated graft survival was 78% for imlifidase and 89% for PLEX, with a slightly higher eGFR in the PLEX arm at the end of the trial. The observed adverse events in the trial were as expected, and there were no apparent differences between the arms.Conclusion: Imlifidase was safe and well‐tolerated in the ABMR population. Despite meeting the primary endpoint of maximum DSA reduction compared to PLEX, the trial was unsuccessful in demonstrating a clinical benefit of imlifidase in this heterogenous ABMR population.Trial Registration: EudraCT number: 2018‐000022‐66, 2020‐004777‐49; ClinicalTrials.gov identifier: NCT03897205, NCT04711850
- 18 July 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (7) , e15383
Open AccessA Randomized Trial Comparing Imlifidase to Plasmapheresis in Kidney Transplant Recipients With Antibody‐Mediated Rejection
Background: Antibody‐mediated rejection (ABMR) poses a barrier to long‐term graft survival and is one of the most challenging events after kidney transplantation. Removing donor specific antibodies (DSA) through therapeutic plasma exchange (PLEX) is a cornerstone of antibody depletion but has inconsistent effects. Imlifidase is a treatment currently utilized for desensitization with near‐complete inactivation of DSA both in the intra‐ and extravascular space.Methods: This was a 6‐month, randomized, open‐label, multicenter, multinational trial conducted at 14 transplant centers. Thirty patients were randomized to either imlifidase or PLEX treatment. The primary endpoint was reduction in DSA level during the 5 days following the start of treatment.Results: Despite considerable heterogeneity in the trial population, DSA reduction as defined by the primary endpoint was 97% for imlifidase compared to 42% for PLEX. Additionally, imlifidase reduced DSA to noncomplement fixing levels, whereas PLEX failed to do so. After antibody rebound in the imlifidase arm (circa days 6–12), both arms had similar reductions in DSA. Five allograft losses occurred during the 6 months following the start of ABMR treatment—four within the imlifidase arm (18 patients treated) and one in the PLEX arm (10 patients treated). In terms of clinical efficacy, the Kaplan–Meier estimated graft survival was 78% for imlifidase and 89% for PLEX, with a slightly higher eGFR in the PLEX arm at the end of the trial. The observed adverse events in the trial were as expected, and there were no apparent differences between the arms.Conclusion: Imlifidase was safe and well‐tolerated in the ABMR population. Despite meeting the primary endpoint of maximum DSA reduction compared to PLEX, the trial was unsuccessful in demonstrating a clinical benefit of imlifidase in this heterogenous ABMR population.Trial Registration: EudraCT number: 2018‐000022‐66, 2020‐004777‐49; ClinicalTrials.gov identifier: NCT03897205, NCT04711850
- Open Access
- 11 August 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (12) , 2011-2012
Response to: The expanded role of the transplant pharmacist: A 10-year follow-up by Lichvar et al
- 11 August 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (12) , 2011-2012
Open AccessResponse to: The expanded role of the transplant pharmacist: A 10-year follow-up by Lichvar et al
- Open Access
- 13 March 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (5) , e14946
The real unmet need: A multifactorial approach for identifying sensitized kidney candidates with low access to transplant
Background: At the start of 2020, the kidney waiting list consisted of 2526 candidates with a calculated panel reactive antibody (CPRA) of 99.9% or greater, a cohort demonstrated in published research to have meaningfully lower than average access to transplantation even under the revised kidney allocation system (KAS).Methods: This was a retrospective analysis of US kidney registrations using data from the OPTN [Reference (https://optn.transplant.hrsa.gov/data/about‐data/)]. The period‐prevalent study cohort consisted of US kidney‐alone registrations who waited at least 1 day between April 1, 2016, when HLA DQ‐Alpha and DP‐Beta unacceptable antigen data became available in OPTN data collection, to December 31, 2019. Poisson rate regression was used to model deceased donor kidney transplant rates per active year waiting and using an offset term to account for differential at‐risk periods. Median time to transplant was estimated for each IRR group using the Kaplan–Meier method. Sensitivity analyses were included to address geographic variation in supply‐to‐demand ratios and differences in dialysis time or waiting time.Results: In this study, we found 1597 additional sensitized (CPRA 50–<99.9%) candidates with meaningfully lower than average access to transplant when simultaneously taking into account CPRA and other factors. In combination with CPRA, candidate blood type, Estimated Post‐Transplant Survival Score (EPTS), and presence of other antibody specificities beyond those in the current, 5‐locus CPRA were found to influence the likelihood of transplant.Conclusion: In total, this suggests approximately 4100 sensitized candidates are on the waiting list who represent a community of disadvantaged patients who may benefit from progressive therapies and interventions to facilitate incompatible transplantation. Though associated with higher risks, such interventions may nevertheless be more attractive than remaining on dialysis with the associated accumulation of mortality risk over time.
- 13 March 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (5) , e14946
Open AccessThe real unmet need: A multifactorial approach for identifying sensitized kidney candidates with low access to transplant
Background: At the start of 2020, the kidney waiting list consisted of 2526 candidates with a calculated panel reactive antibody (CPRA) of 99.9% or greater, a cohort demonstrated in published research to have meaningfully lower than average access to transplantation even under the revised kidney allocation system (KAS).Methods: This was a retrospective analysis of US kidney registrations using data from the OPTN [Reference (https://optn.transplant.hrsa.gov/data/about‐data/)]. The period‐prevalent study cohort consisted of US kidney‐alone registrations who waited at least 1 day between April 1, 2016, when HLA DQ‐Alpha and DP‐Beta unacceptable antigen data became available in OPTN data collection, to December 31, 2019. Poisson rate regression was used to model deceased donor kidney transplant rates per active year waiting and using an offset term to account for differential at‐risk periods. Median time to transplant was estimated for each IRR group using the Kaplan–Meier method. Sensitivity analyses were included to address geographic variation in supply‐to‐demand ratios and differences in dialysis time or waiting time.Results: In this study, we found 1597 additional sensitized (CPRA 50–<99.9%) candidates with meaningfully lower than average access to transplant when simultaneously taking into account CPRA and other factors. In combination with CPRA, candidate blood type, Estimated Post‐Transplant Survival Score (EPTS), and presence of other antibody specificities beyond those in the current, 5‐locus CPRA were found to influence the likelihood of transplant.Conclusion: In total, this suggests approximately 4100 sensitized candidates are on the waiting list who represent a community of disadvantaged patients who may benefit from progressive therapies and interventions to facilitate incompatible transplantation. Though associated with higher risks, such interventions may nevertheless be more attractive than remaining on dialysis with the associated accumulation of mortality risk over time.
- Open Access
- 1 September 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (3) , 691-697
Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation
- 1 September 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (3) , 691-697
Open AccessImlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation
- Open Access
- 8 July 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (12) , 3907-3918
Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients
- 8 July 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (12) , 3907-3918
Open AccessOutcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients
- Open Access
- 3 June 2021
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 05 (02) , 1-15
Beyond CPRA: Identifying Sensitized Kidney Candidates with Markedly Low Access to Deceased Donor Transplantation by Granular CPRA and Blood Type
Prioritization in the US Kidney Allocation System (KAS) has led to an improvement in the rates of transplantation in highly sensitized (HS) patients. However, there is a subset of HS patients who are at a disadvantage, despite prioritization under KAS. The purpose of this study was to describe the transplant rate (TR) by calculated panel reactive antibody (CPRA) of HS candidates before and five years post-KAS to characterize their access to deceased donor transplants and quantify the number of HS candidates who are at a marked disadvantage in accessing kidneys. Using de-identified OPTN data, the number of solitary deceased donor kidney transplants performed (by month) from June 2013 through December 2019 was analyzed for four CPRA groups (95–97%, 98%, 99%, and 100%), with the CPRA 100% group further stratified into two subgroups (99.5–99.9% and >99.9%). The impact of the recipient blood group was assessed as an additional factor in TR. Immediately after KAS, TR rose 7-fold from 0.26% to 1.7% for the CPRA 99–100% group as a whole, and 12-fold and 8-fold for the CPRA 99.5–99.9% and CPRA 99.9%+ groups, respectively. However, the post-KAS mean TR of 0.63% for CPRA 99.9%+ candidates remained markedly lower than the mean TR of the other sensitized groups: 1.5% for CPRA 95–97%, 1.4% for CPRA 98%, 2.0% for CPRA 99%, and 3.5% for CPRA 99.5–99.9%; a statistically significant 6-fold advantage of the CPRA 99.5–99.9% group over CPRA 99.9%+ candidates was observed, despite both groups receiving national priority under KAS. Patients with a CPRA of 99.9%+ and blood group B were 2.16, 1.98, and 1.75 times less likely to receive a transplant compared to the same CPRA group with blood groups A, AB, and O, respectively, despite changes to KAS allocating blood type A2 and A2B to recipients with blood group B. Although the TR increased sharply for the CPRA 99.9%+ group with KAS, it remained markedly lower than the average despite national priority.
- 3 June 2021
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 05 (02) , 1-15
Open AccessBeyond CPRA: Identifying Sensitized Kidney Candidates with Markedly Low Access to Deceased Donor Transplantation by Granular CPRA and Blood Type
Prioritization in the US Kidney Allocation System (KAS) has led to an improvement in the rates of transplantation in highly sensitized (HS) patients. However, there is a subset of HS patients who are at a disadvantage, despite prioritization under KAS. The purpose of this study was to describe the transplant rate (TR) by calculated panel reactive antibody (CPRA) of HS candidates before and five years post-KAS to characterize their access to deceased donor transplants and quantify the number of HS candidates who are at a marked disadvantage in accessing kidneys. Using de-identified OPTN data, the number of solitary deceased donor kidney transplants performed (by month) from June 2013 through December 2019 was analyzed for four CPRA groups (95–97%, 98%, 99%, and 100%), with the CPRA 100% group further stratified into two subgroups (99.5–99.9% and >99.9%). The impact of the recipient blood group was assessed as an additional factor in TR. Immediately after KAS, TR rose 7-fold from 0.26% to 1.7% for the CPRA 99–100% group as a whole, and 12-fold and 8-fold for the CPRA 99.5–99.9% and CPRA 99.9%+ groups, respectively. However, the post-KAS mean TR of 0.63% for CPRA 99.9%+ candidates remained markedly lower than the mean TR of the other sensitized groups: 1.5% for CPRA 95–97%, 1.4% for CPRA 98%, 2.0% for CPRA 99%, and 3.5% for CPRA 99.5–99.9%; a statistically significant 6-fold advantage of the CPRA 99.5–99.9% group over CPRA 99.9%+ candidates was observed, despite both groups receiving national priority under KAS. Patients with a CPRA of 99.9%+ and blood group B were 2.16, 1.98, and 1.75 times less likely to receive a transplant compared to the same CPRA group with blood groups A, AB, and O, respectively, despite changes to KAS allocating blood type A2 and A2B to recipients with blood group B. Although the TR increased sharply for the CPRA 99.9%+ group with KAS, it remained markedly lower than the average despite national priority.
- 6 November 2020
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 41 (1) , 132-143
Advances in personalized medicine and noninvasive diagnostics in solid organ transplantation
Personalized medicine has been a mainstay and in practice in transplant pharmacotherapy since the advent of the field. Decisions pertaining to the diagnosis, selection, and monitoring of transplant pharmacotherapy are aimed toward the individual, the allograft, and the overall immunologic needs of the patient. Recent advances in pharmacogenomics, noninvasive biomarkers, and artificial intelligence (AI) technologies have the promise of transforming the way we individualize treatment and monitor allograft function. Pharmacogenomic testing can provide clinicians with additional data that can minimize toxicity and maximize therapeutic dosing in high‐risk patients, leading to more informed decisions that may decrease the risk of rejection and adverse outcomes related to immunosuppressive therapies. Development of noninvasive strategies to monitor allograft function may offer safer and more convenient methods to detect allograft injury. Cell free DNA and gene expression profiling offer the potential to serve as “liquid biopsies” minimizing the risk to patients and providing clinicians with useful molecular data that may help individualize immunosuppression and rejection treatment. Use of big data in transplant and novel AI platforms, such as the iBox, hold tremendous promise in providing clinicians a “glimpse into the future” thereby allowing for a more individualized approach to immunosuppressive therapy that may minimize future adverse outcomes. Advances in diagnostics, laboratory science, and AI have made the application of personalized medicine even more tailored for solid organ transplant recipients. In this perspective, we summarize the current and emerging tools available, literature supporting use, and the horizon for future personalization of transplantation.
- 6 November 2020
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 41 (1) , 132-143
Advances in personalized medicine and noninvasive diagnostics in solid organ transplantation
Personalized medicine has been a mainstay and in practice in transplant pharmacotherapy since the advent of the field. Decisions pertaining to the diagnosis, selection, and monitoring of transplant pharmacotherapy are aimed toward the individual, the allograft, and the overall immunologic needs of the patient. Recent advances in pharmacogenomics, noninvasive biomarkers, and artificial intelligence (AI) technologies have the promise of transforming the way we individualize treatment and monitor allograft function. Pharmacogenomic testing can provide clinicians with additional data that can minimize toxicity and maximize therapeutic dosing in high‐risk patients, leading to more informed decisions that may decrease the risk of rejection and adverse outcomes related to immunosuppressive therapies. Development of noninvasive strategies to monitor allograft function may offer safer and more convenient methods to detect allograft injury. Cell free DNA and gene expression profiling offer the potential to serve as “liquid biopsies” minimizing the risk to patients and providing clinicians with useful molecular data that may help individualize immunosuppression and rejection treatment. Use of big data in transplant and novel AI platforms, such as the iBox, hold tremendous promise in providing clinicians a “glimpse into the future” thereby allowing for a more individualized approach to immunosuppressive therapy that may minimize future adverse outcomes. Advances in diagnostics, laboratory science, and AI have made the application of personalized medicine even more tailored for solid organ transplant recipients. In this perspective, we summarize the current and emerging tools available, literature supporting use, and the horizon for future personalization of transplantation.
- Open Access
- 9 December 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 20 (2) , 362-376
C4 article: Challenges and solutions to appropriate and timely medication access in transplantation in the United States
- 9 December 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 20 (2) , 362-376
Open AccessC4 article: Challenges and solutions to appropriate and timely medication access in transplantation in the United States
- Open Access
- 24 March 2019
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 2 (3) , 288-302
PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas
Clinical pharmacists have been incorporating precision medicine into practice for decades. Drug selection and dosing based on patient‐specific clinical factors such as age, weight, renal function, drug interactions, plasma drug concentrations, and diet are expected as part of routine clinical practice. Newer concepts of precision medicine such as pharmacogenomics have recently been implemented into clinical care, while other concepts such as epigenetics and pharmacomicrobiomics still predominantly exist in the research area but clinical translation is expected in the future. The purpose of this paper is to describe current and emerging aspects of precision medicine as it relates to clinical pharmacy across a variety of specialty areas of practice, with perspectives from the American College of Clinical Pharmacy Practice and Research Network membership.
- 24 March 2019
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 2 (3) , 288-302
Open AccessPRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas
Clinical pharmacists have been incorporating precision medicine into practice for decades. Drug selection and dosing based on patient‐specific clinical factors such as age, weight, renal function, drug interactions, plasma drug concentrations, and diet are expected as part of routine clinical practice. Newer concepts of precision medicine such as pharmacogenomics have recently been implemented into clinical care, while other concepts such as epigenetics and pharmacomicrobiomics still predominantly exist in the research area but clinical translation is expected in the future. The purpose of this paper is to describe current and emerging aspects of precision medicine as it relates to clinical pharmacy across a variety of specialty areas of practice, with perspectives from the American College of Clinical Pharmacy Practice and Research Network membership.